SFSIG
ICPT

San Francisco Sentry Investment Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

San Francisco Sentry Investment Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7
Closed -$1K – 1086
2018
Q4 		$1K Buy
+7
New +$726 ﹤0.01% 943

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

San Francisco Sentry Investment Group's ICPT Position: Q1 2019 in Review

San Francisco Sentry Investment Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2019, closing a stake of 7 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in ICPT in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

  • San Francisco Sentry Investment Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 7 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • San Francisco Sentry Investment Group's Intercept Pharmaceuticals, Inc. position peaked at $1K in Q4 2018.
  • 202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q1 2019, filed 8 May 2019.